DRP-104 (sirpiglenastat) represents a novel prodrug of the broad-spectrum glutamine antagonist DON
PROHIBITED USES: Our products are explicitly NOT intended for: Human consumption, injection, ingestion, or application in any form Veterinary or animal use of any kind Food, beverage, or dietary supplement applications Cosmetic or personal care applications Clinical, therapeutic, diagnostic, or medical applications Any use outside of legitimate laboratory research FDA Regulatory Status NOT FDA APPROVED: None of our products have been evaluated, approved, or regulated by the U.S
This theory involves multiple genes, most of which correspond to the immune system, with a smaller number involving melanocytes
This is sufficient for multi-dose vial use because the preservative continuously suppresses any small microbial load introduced during punctures, preventing it from reaching levels that pose contamination risk
For subcutaneous injection, either form works effectively
Other expert panels appointed under Kennedy have faced criticism for apparent conflicts of interest
